Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bide Pharmatech CoSHSE:688073 +9.28%86 EV-to-FCF is 92.03 as of Aug. 04, 2026, which is 101% above its 10-year median of 45.83. GuruFocus rates SHSE:688073 with a GF Score™ of 86/100 and a GF Value™ of ¥67.40 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 572 Drug Manufacturers companies, Bide Pharmatech Co ranks worse than 86.71% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bide Pharmatech Co's Enterprise Value is ¥3,269 Mil.
Bide Pharmatech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥36 Mil. Therefore, Bide Pharmatech Co's EV-to-FCF for today is 92.03.
The historical rank and industry rank for Bide Pharmatech Co's EV-to-FCF or its related term are showing as below:
SHSE:688073'
s EV-to-FCF Range Over the Past 10 Years
Min: -1554.85 Med: 45.83 Max: 1325.68
Current: 104.85
During the past 8 years, the highest EV-to-FCF of Bide Pharmatech Co was 1325.68. The lowest was -1554.85. And the median was 45.83.
SHSE:688073's EV-to-FCF is ranked worse than 86.71% of 572
companies
in the Drug Manufacturers industry
Industry Median: 21.06
vs SHSE:688073: 104.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bide Pharmatech Co (SHSE:688073) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bide Pharmatech Co's PE Ratio (TTM) for today is calculated as:
Bide Pharmatech Co's share price for today is ¥50.65.
Bide Pharmatech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bide Pharmatech Co EV-to-FCF Related Terms
Bide Pharmatech Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bide Pharmatech Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bide Pharmatech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bide Pharmatech Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bide Pharmatech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bide Pharmatech Co's EV-to-FCF falls into.
Bide Pharmatech Co's current Enterprise Value is ¥3,269 Mil.
Bide Pharmatech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bide Pharmatech Co (SHSE:688073) has a EV-to-FCF of 92.03 as of Aug. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bide Pharmatech Co and its competitors. This is 101% above median its historical median of 45.83. According to the industry distribution chart, Bide Pharmatech Co ranks #496 out of 572 companies in the Drug Manufacturers industry, placing it in the top 86.7%.
Is Bide Pharmatech Co's EV-to-FCF too high?
Bide Pharmatech Co's current EV-to-FCF of 92.03 is 101% above median its 10-year median of 45.83. The Drug Manufacturers industry median EV-to-FCF is 21.06. Bide Pharmatech Co's value of 92.03 is 337% above this industry median. Based on the distribution chart, Bide Pharmatech Co ranks #496 out of 572 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bide Pharmatech Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bide Pharmatech Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bide Pharmatech Co ranks #496 out of 572 companies for EV-to-FCF. This places Bide Pharmatech Co in the lower half of its industry. The industry median EV-to-FCF is 21.06. Bide Pharmatech Co's value of 92.03 is 337% above this benchmark. While the company's 10-year median is 45.83 vs. the industry median of 21.06, Bide Pharmatech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 572 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bide Pharmatech Co's current EV-to-FCF of 92.03 is 337% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bide Pharmatech Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bide Pharmatech Co's current EV-to-FCF is 92.03, which is 101% above median its own 10-year median of 45.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bide Pharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, Bide Pharmatech Co (SHSE:688073) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥67.40, compared to a current price of ¥50.65 — trading 24.9% below its estimated fair value. The current EV-to-FCF is 92.03, which is 101% above median its 10-year median of 45.83 and 337% above the Drug Manufacturers industry median of 21.06. Bide Pharmatech Co's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bide Pharmatech Co (SHSE:688073), the current EV-to-FCF is 92.03 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bide Pharmatech Co (SHSE:688073) Overvalued in 2026?
Based on GuruFocus' analysis, Bide Pharmatech Co stock appears to be undervalued.
The current stock price of ¥50.65 is trading 24.9% below its estimated GF Value™ of ¥67.40.
GuruFocus considers Bide Pharmatech Co to be Modestly Undervalued.
Key valuation signals for SHSE:688073:
EV-to-FCF: 92.03 (101% above median its 10-year median of 45.83)
GF Value™: ¥67.40 vs. price of ¥50.65 (24.9% below fair value)
Industry Position: 337% above the Drug Manufacturers median (#496 of 572)
No single metric tells the full story. See the SHSE:688073 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688073 has been successfully added to your 
